A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)

Japanese Journal of Clinical Oncology

Volumn 44, Issue 4, 2014, Pages 379-382

  Eba, Junko ^a   Kenmotsu, Hirotsugu ^b   Tsuboi, Masahiro ^c   Niho, Seiji ^d   Katayama, Hiroshi ^a   Shibata, Taro ^a   Watanabe, Shun ichi ^e   Yamamoto, Noboru ^e   Tamura, Tomohide ^e   Asamura, Hisao ^e  

^a NATIONAL CANCER CENTER   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Adjuvant chemotherapy; High grade neuroendocrine carcinoma; Lung neoplasms; Phase III

Indexed keywords

CISPLATIN; CREATININE; ETOPOSIDE; IRINOTECAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPOKALEMIA; HYPONATREMIA; JAPAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MYALGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; REPEATED DRUG DOSE; SECOND CANCER; SENSORY NEUROPATHY; SIDE EFFECT;

ADJUVANT CHEMOTHERAPY; HIGH-GRADE NEUROENDOCRINE CARCINOMA; LUNG NEOPLASMS; PHASE III;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NEUROENDOCRINE; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL PROTOCOLS; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; INCIDENCE; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PATIENT SELECTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84897475114     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt233     Document Type: Article

References (19)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44.
2. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002;124:285-92.
3. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-53.
4. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006;24:70-6.
5. Badzio A, Kurowski K, Karnicka-Mlodkowska H, Jassem J. A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 2004;26:183-8.
6. Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005;129:977-83.
7. Davis S, Crino L, Tonato M, Darwish S, Pelicci PG, Grignani F. A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer. Am J Clin Oncol 1993;16:93-5.
8. Iyoda A, Hiroshima K, Moriya Y, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006;82:1802-7.
9. Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005;23:8774-85.
10. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
11. Hanna N, Bunn PA, Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-43.
12. Lara PN, Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5.
13. Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010;21:1810-6.
14. Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867-73.
15. Kenmotsu H, Niho S, Ito T, et al. A pilot study of adjuvant chemotherapy with cisplatin and irinotecan for high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). ASCO Meeting Abstracts, 2011;29(15 suppl):7076.
16. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumours. 7th ed. New York:Wiley-Blackwell 2010.
17. The Japan Lung Cancer Society. General Rule for Clinical and Pathological Record of Lung Cancer. 7th ed. Tokyo: Kanehara Shuppan 2010 (in Japanese).
18. Schoenfeld DR, Richter J. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982;38:163-70.
19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.